CJC-1295

CJC-1295 with DAC (Drug Affinity Complex) has a lysine modification enabling albumin binding, extending half-life from minutes to approximately 8 days — creating a continuous GH baseline elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a 30-minute half-life and produces a sharper, more pulsatile GH release. Most research protocols prefer the no-DAC version stacked with Ipamorelin for more physiological GH pulsatility.

Initial increases in IGF-1 levels are typically measurable within 1–2 weeks. Body composition changes — improved muscle tone, reduced fat, better recovery — are most commonly reported after 8–12 weeks of consistent use. Sleep quality improvements are often reported within the first few weeks.

CJC-1295 acts on the GHRH receptor (via cAMP pathway) while Ipamorelin acts on GHS-R1a (via IP3/DAG pathway). These are complementary mechanisms — combining them produces significantly greater GH pulse amplitude than either alone. Ipamorelin's selectivity also prevents the cortisol and prolactin elevation that would occur with older GH secretagogues.

For CJC-1295 without DAC: 100–300 mcg per injection, typically combined with 100–300 mcg Ipamorelin, administered subcutaneously 2–3x daily (before bed and morning are most common). For CJC-1295 with DAC: 1–2 mg once weekly due to the extended half-life. Cycle length is typically 12–16 weeks.